Literature DB >> 22623528

Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.

Leopold Kong1, Erick Giang, Justin B Robbins, Robyn L Stanfield, Dennis R Burton, Ian A Wilson, Mansun Law.   

Abstract

Hepatitis C virus (HCV) infects more than 2% of the global population and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and end-stage liver diseases. Circulating HCV is genetically diverse, and therefore a broadly effective vaccine must target conserved T- and B-cell epitopes of the virus. Human mAb HCV1 has broad neutralizing activity against HCV isolates from at least four major genotypes and protects in the chimpanzee model from primary HCV challenge. The antibody targets a conserved antigenic site (residues 412-423) on the virus E2 envelope glycoprotein. Two crystal structures of HCV1 Fab in complex with an epitope peptide at 1.8-Å resolution reveal that the epitope is a β-hairpin displaying a hydrophilic face and a hydrophobic face on opposing sides of the hairpin. The antibody predominantly interacts with E2 residues Leu(413) and Trp(420) on the hydrophobic face of the epitope, thus providing an explanation for how HCV isolates bearing mutations at Asn(415) on the same binding face escape neutralization by this antibody. The results provide structural information for a neutralizing epitope on the HCV E2 glycoprotein and should help guide rational design of HCV immunogens to elicit similar broadly neutralizing antibodies through vaccination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623528      PMCID: PMC3386053          DOI: 10.1073/pnas.1202924109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  Prospects for a vaccine against the hepatitis C virus.

Authors:  Michael Houghton; Sergio Abrignani
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

2.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

3.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

5.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Authors:  Meital Gal-Tanamy; Zhen-Yong Keck; MinKyung Yi; Jane A McKeating; Arvind H Patel; Steven K H Foung; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

7.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.

Authors:  Mansun Law; Toshiaki Maruyama; Jamie Lewis; Erick Giang; Alexander W Tarr; Zania Stamataki; Pablo Gastaminza; Francis V Chisari; Ian M Jones; Robert I Fox; Jonathan K Ball; Jane A McKeating; Norman M Kneteman; Dennis R Burton
Journal:  Nat Med       Date:  2007-12-06       Impact factor: 53.440

8.  Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.

Authors:  Zhen-Yong Keck; Ta-Kai Li; Jinming Xia; Meital Gal-Tanamy; Oakley Olson; Sophia H Li; Arvind H Patel; Jonathan K Ball; Stanley M Lemon; Steven K H Foung
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

9.  Nomenclature and numbering of the hepatitis C virus.

Authors:  Carla Kuiken; Peter Simmonds
Journal:  Methods Mol Biol       Date:  2009

Review 10.  Structure-based antigen design: a strategy for next generation vaccines.

Authors:  Philip R Dormitzer; Jeffrey B Ulmer; Rino Rappuoli
Journal:  Trends Biotechnol       Date:  2008-10-30       Impact factor: 19.536

View more
  94 in total

Review 1.  Computational tools for epitope vaccine design and evaluation.

Authors:  Linling He; Jiang Zhu
Journal:  Curr Opin Virol       Date:  2015-03-31       Impact factor: 7.090

2.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

3.  Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors.

Authors:  Fernando Aleman; Netanel Tzarum; Leopold Kong; Kenna Nagy; Jiang Zhu; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

Review 4.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

5.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Authors:  Andrew I Flyak; Stormy Ruiz; Michelle D Colbert; Tiffany Luong; James E Crowe; Justin R Bailey; Pamela J Bjorkman
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

Review 6.  A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes.

Authors:  Edgar Davidson; Benjamin J Doranz
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

7.  Hepatitis C virus E2 envelope glycoprotein core structure.

Authors:  Leopold Kong; Erick Giang; Travis Nieusma; Rameshwar U Kadam; Kristin E Cogburn; Yuanzi Hua; Xiaoping Dai; Robyn L Stanfield; Dennis R Burton; Andrew B Ward; Ian A Wilson; Mansun Law
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

8.  Rational HIV immunogen design to target specific germline B cell receptors.

Authors:  Joseph Jardine; Jean-Philippe Julien; Sergey Menis; Takayuki Ota; Oleksandr Kalyuzhniy; Andrew McGuire; Devin Sok; Po-Ssu Huang; Skye MacPherson; Meaghan Jones; Travis Nieusma; John Mathison; David Baker; Andrew B Ward; Dennis R Burton; Leonidas Stamatatos; David Nemazee; Ian A Wilson; William R Schief
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

9.  Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.

Authors:  Tinashe B Ruwona; Erick Giang; Travis Nieusma; Mansun Law
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

10.  Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Authors:  Zhen-yong Keck; Christine Girard-Blanc; Wenyan Wang; Patrick Lau; Adam Zuiani; Felix A Rey; Thomas Krey; Michael S Diamond; Steven K H Foung
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.